Compare Amgen, Inc. (AMGN) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Old Dominion Freight Line Inc — how do they compare? Amgen, Inc. trades at $413.07 (market cap $225.71B), while Old Dominion Freight Line Inc trades at $209.64 (market cap $44.07B). The key difference: Amgen, Inc. is far larger — about 5.1× Old Dominion Freight Line Inc's market cap, and Amgen, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AMGN | ODFL | |
|---|---|---|
Market Cap | $225.71B | $44.07B |
Sector | Health | Industrials |
52-Week High | $417.20 | $248.73 |
52-Week Low | $271.18 | $126.29 |
Enterprise Value | $269.02B | $43.81B |
Dividend Yield | 2.42% | 0.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
ODFL stock trades at $216.36, up 2.34% today, with a bearish technical signal but strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $1.68 versus $1.54 expected, driven by yield improvements and cost discipline. The company maintains robust profitability with a net income margin of 19.44% and ROE of 24.82%, though revenue has declined from $6.3B in 2022 to $5.5B in 2025. Analyst consensus price target is $239.85, suggesting upside potential.
Outlook is mixed: earnings momentum and a solid balance sheet support growth, but high valuation ratios (P/E of 41.6) and freight volume pressures pose risks. Investors should weigh the premium pricing against operational efficiency gains and market recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
